Skip to main content

Palvella Therapeutics, Inc.

corporate_fare Company Profile

Palvella Therapeutics, Inc.

PVLA·NASDAQ·Life Sciences·CIK 0001583648

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack FDA-approved treatments. On December 13, 2024, the company completed a business combination with Legacy Palvella, resulting in Legacy Palvella becoming a wholly-owned subsidiary and the company changing its name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. Its business is now primarily that of Legacy Palvella. The company aims to become a leader in rare disease biopharmaceuticals by providing improved treatment options that address the underlying causes of these conditions. Palvella leverages its QTORIN platform, designed to generate novel topical product candidates that penetrate deep skin layers for local treatment of a broad range of rare skin diseases and vascular malformations. The company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for PVLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PVLA spans 8-K, 10-Q.

Recent high-impact activity:

  • Palvella Unveils Third QTORIN Program: Topical Docetaxel for EMPD
  • Palvella Q3: $236.7M Cash, Net Loss Widens to $24.6M Ahead of Feb 28, 2027 PDUFA
  • Palvella Posts $24.6M Q3 Loss, $236.7M Cash Ahead of Feb 2027 PDUFA
  • FDA Accepts Palvella's QTORIN Rapamycin NDA, Grants Priority Review; PDUFA Set for Feb 28, 2027
  • FDA Accepts NDA, Grants Priority Review for Rare Disease Therapy With Feb 2027 PDUFA

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$41.72M
Diluted EPS
-$3.71
Op. Cash Flow
-$25.01M
Operating Income
-$38.6M
Cash & Equivalents
$57.98M
Debt / Equity
0.00×
Shares Outstanding
12.38M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-133372

Short Interest & Short Volume

11.46 days to cover

FINRA reported short interest of 2,601,661 shares in PVLA as of the October 30, 2026 settlement, a 8.1% increase from the prior period — about 11.5 days to cover at its recent average daily volume. On November 20, 2026, 53.8% of PVLA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,601,661 shares as of October 30, 2026
Change vs prior period▲ 8.1%
Days to cover11.46 at avg daily volume of 226,984
Daily short volume (FINRA facilities)53.8% of 64,140 shares on November 20, 2026
5-day average short volume50.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$142.85
52-week range · as of 2026-11-19 $72.22 – $179.95
Market cap
$2.09B
Volume
192.7K (0.7× avg)
3-mo avg 263.6K
Live data · 2026-11-21 07:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PVLA - Latest Insights

PVLA
Nov 19, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $147.00
Real-time Price: $142.85 info
Change: -$4.15 (-3%) info
Market Cap: $2.088B info
PVLA
Nov 05, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $153.30
Real-time Price: $142.85 info
Change: -$10.45 (-7%) info
Market Cap: $2.088B info
PVLA
Nov 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.30
Real-time Price: $142.85 info
Change: -$10.45 (-7%) info
Market Cap: $2.088B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $127.00
Real-time Price: $142.85 info
Change: +$15.85 (+12%) info
Market Cap: $2.088B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $134.99
Real-time Price: $142.85 info
Change: +$7.86 (+6%) info
Market Cap: $2.088B info
PVLA
Aug 31, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $150.34
Real-time Price: $142.85 info
Change: -$7.49 (-5%) info
Market Cap: $2.088B info
PVLA
Aug 04, 2026, 7:51 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $140.80
Real-time Price: $142.85 info
Change: +$2.05 (+1%) info
Market Cap: $2.088B info
PVLA
Aug 04, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $140.80
Real-time Price: $142.85 info
Change: +$2.05 (+1%) info
Market Cap: $2.088B info
PVLA
Aug 04, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $140.80
Real-time Price: $142.85 info
Change: +$2.05 (+1%) info
Market Cap: $2.088B info
PVLA
Jul 14, 2026, 4:48 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $149.68
Real-time Price: $142.85 info
Change: -$6.83 (-5%) info
Market Cap: $2.088B info
PVLA
Jun 30, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $154.90
Real-time Price: $142.85 info
Change: -$12.05 (-8%) info
Market Cap: $2.088B info
PVLA
Jun 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $116.51
Real-time Price: $142.85 info
Change: +$26.34 (+23%) info
Market Cap: $2.088B info
PVLA
May 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $117.59
Real-time Price: $142.85 info
Change: +$25.26 (+21%) info
Market Cap: $2.088B info
PVLA
May 20, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $115.50
Real-time Price: $142.85 info
Change: +$27.35 (+24%) info
Market Cap: $2.088B info
PVLA
May 20, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $115.50
Real-time Price: $142.85 info
Change: +$27.35 (+24%) info
Market Cap: $2.088B info
PVLA
May 15, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $120.59
Real-time Price: $142.85 info
Change: +$22.26 (+18%) info
Market Cap: $2.088B info
PVLA
May 13, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $126.00
Real-time Price: $142.85 info
Change: +$16.85 (+13%) info
Market Cap: $2.088B info
PVLA
May 07, 2026, 9:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $130.17
Real-time Price: $142.85 info
Change: +$12.68 (+10%) info
Market Cap: $2.088B info
PVLA
May 07, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $130.17
Real-time Price: $142.85 info
Change: +$12.68 (+10%) info
Market Cap: $2.088B info
PVLA
May 07, 2026, 7:34 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $130.17
Real-time Price: $142.85 info
Change: +$12.68 (+10%) info
Market Cap: $2.088B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets